Recruiting for their new Swedish bioanalytical laboratory

With a broad portfolio of analytical instruments, software solutions, chemicals, reagents and pharmaceutical services, Thermo Fisher supports customers in research, drug development, diagnostics and industrial markets globally.

“The mission of Thermo Fisher is to enable our customers to make the world healthier, cleaner and safer. We operate globally and use the most technologically advanced systems to support our customers and sponsors,” says Niveen Mulholland, vice president, bioanalytical and vaccine sciences, clinical research, at Thermo Fisher.

“The new bioanalytical laboratory is going to meet the needs of our pharmaceutical and biotech customers in Europe and support them with the high quality, consistent, timely data that they need. Alongside the expertise of our specialist scientists, the new lab will provide leading-edge instrumentation across all clinical phases of the pharmaceutical development and really help our customers deliver life-changing medicines to patients worldwide.”

Opportunities for collaboration

The new bioanalytical laboratory will be located at the global research cluster GoCo Health Innovation City in Mölndal, which will situate Thermo Fisher close to customers, sponsors, biotech startups, and academic institutions, as well as the AstraZeneca campus and the AstraZeneca BioVentureHub.

“The GoCo Health Innovation City is an amazing global research cluster that gives us great opportunities for collaboration,” Mulholland said. “The focus on healthcare, medicine and sustainability is very aligned with our mission. From Gothenburg, we’ll be able to support customers and sponsors worldwide, but will be positioned to focus on European customers.”

The 3000 square-meter bioanalytical laboratory will include a wide range of advanced technologies and methodologies, such as cell-based assays, chromatography, flow cytometry, immunochemistry, proteomics and molecular genomics - which will make the laboratory similar to the company’s current bioanalytical labs in the U.S. and China.

“We support preclinical work in terms of research, method development and method validation, and are really focused on method development and sample analysis through all phases of the clinical trial,” says Mulholland, who has a Ph.D. in genetics and has worked for over 10 years at Thermo Fisher. “The new lab will support all therapeutic areas, including cardiology studies, and oncology studies, infectious disease. The lab will also support a broad range of modalities. There is currently a significant interest in antibody drug conjugates (ADCs), where we are world leaders. We’ll also have capability to study classic molecules, other biologics, and oligonucleotides. There seems to be some interest in the region for oligos.”

Successful history in Sweden

The venture is the latest of several successful investments in Sweden by Thermo Fisher, which has other facilities in the Nordic country. The company has a logistics and service center in Hisingen, Gothenburg, and its Olink proteomics business in Uppsala, north of Stockholm.

“Proteomics is the large-scale, comprehensive study of the entire set of proteins, and with the new lab in Gothenburg we can expand our proteomics service offering in partnership with our colleagues in Uppsala,” Mulholland says. “We’ll be able to provide a comprehensive picture of disease phenotypes and mechanisms through the proteomics platform.”

In the last quarter of 2025, Thermo Fisher will complete the bioanalytical laboratory in GoCo Health Innovation City and the company is on schedule to move into the lab in January to start the fit out and then begin operations in March 2026. This fall, the company is recruiting highly skilled scientists and laboratory support professionals, and are open for applications.

“The best way for anyone interested is to visit the Thermo Fisher career site, jobs.thermofisher.com,” Mulholland says. “You can also meet us at the Nordic Life Science Days, where our new site leader for the Gothenburg lab will be in attendance. Our president of analytical services, Leon Wyszkowski, will also attend the Nordic Life Science Days, and will be on a panel discussing culture as a competitive advantage on October 14.”